{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:00:33Z","timestamp":1793106033526,"version":"4.5.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A., Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To describe clinical and biochemical characteristics, including health-related quality of life (HRQoL), in patients with chronic hypoparathyroidism (cHypoPT) who were receiving conventional therapy (calcium and active vitamin D), and to compare baseline HRQoL between patients who subsequently received recombinant human parathyroid hormone (1-84) (rhPTH [1-84]) and those who did not.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Cross-sectional analysis of data recorded at enrollment (baseline) from patients with cHypoPT in the PARADIGHM registry before May 31, 2022.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eligible patients were aged \u226518 years and receiving conventional therapy at enrollment. Health-related quality of life was measured using the 36-Item Short-Form Health Survey version 2 (SF-36v2), Work Productivity and Activity Impairment Specific Health Problem (WPAI:SHP) questionnaire, and the Hypoparathyroidism Symptom Diary (HypoPT-SD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eligible patients (N = 1070) were mostly female (80.7%) and White (86.0%). Surgery was the most common cause of cHypoPT (82.2%). Mean serum albumin-adjusted calcium, phosphate, and calcium\u2013phosphate product levels were within the target ranges. Mean (standard deviation [SD]) SF-36v2 physical and mental component scores were 46.3 (10.2) and 47.6 (11.5), respectively (normative scores: 50). Patients who went on to receive rhPTH (1-84) (n = 102) had significantly worse baseline HRQoL scores than patients in the conventional therapy group (n = 968) for all SF-36v2 and HypoPT-SD parameters and most WPAI parameters. There were no meaningful differences in biochemical parameters between the groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Thirty-six-Item Short-Form Health Survey version 2 scores in patients with cHypoPT were lower than the normalized values reported previously for the US population. Patients who were subsequently prescribed rhPTH (1-84) had worse baseline HRQoL scores than those in the conventional therapy group.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvaf169","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:19:24Z","timestamp":1759846764000},"page":"428-439","source":"Crossref","is-referenced-by-count":4,"title":["Health-related quality of life in a cohort of 1070 patients with hypoparathyroidism"],"prefix":"10.1093","volume":"193","author":[{"given":"Heide","family":"Siggelkow","sequence":"first","affiliation":[{"name":"Department of Trauma, Orthopedic and Reconstructive Surgery, University Medical Center G\u00f6ttingen , Robert-Koch-Str., 37075 G\u00f6ttingen ,","place":["Germany"]},{"name":"Center of Endocrine Diseases, Endokrinologikum G\u00f6ttingen , Von-Siebold-Str, 37075 G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Vokes","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago , Chicago, IL 60637 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Gittoes","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology, Diabetes and Metabolism, Queen Elizabeth Hospital , Birmingham B15 2TH ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6084-5900","authenticated-orcid":false,"given":"Olulade","family":"Ayodele","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. , Cambridge, MA 02142 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[{"name":"Fondazione Italiana Ricerca Sulle Malattie dell\u2019Osso (FIRMO Onlus) , Florence 50129 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Castriota","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. , Cambridge, MA 02142 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0036-7809","authenticated-orcid":false,"given":"Michael A","family":"Levine","sequence":"additional","affiliation":[{"name":"Center for Bone Health and the Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine , Philadelphia, PA 19104 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Schaeffer Koziol","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A. Inc. , Cambridge, MA 02142 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Rejnmark","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Internal Medicine, Aarhus University Hospital , 8200 Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya A","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, McMaster University , Hamilton, Ontario, L8N 3Z5 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinggao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A. Inc. , Cambridge, MA 02142 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Marelli","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG , 8152 Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Germak","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A. Inc. , Cambridge, MA 02142 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0867-9778","authenticated-orcid":false,"given":"Michael","family":"Mannstadt","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital and Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"issue":"6","key":"2025100710005545200_lvaf169-B1","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1210\/jc.2015-3907","article-title":"Management of hypoparathyroidism: summary statement and guidelines","volume":"101","author":"Brandi","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025100710005545200_lvaf169-B2","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1002\/jbmr.4691","article-title":"Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop","volume":"37","author":"Khan","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025100710005545200_lvaf169-B3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4158\/EP13328.OR","article-title":"Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study","volume":"20","author":"Hadker","year":"2014","journal-title":"Endocr Pract"},{"issue":"2","key":"2025100710005545200_lvaf169-B4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/cen.14128","article-title":"Burden of illness in not adequately controlled chronic hypoparathyroidism: findings from a 13-country patient and caregiver survey","volume":"92","author":"Siggelkow","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2025100710005545200_lvaf169-B5","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1007\/s12325-021-01787-7","article-title":"Risk of cardiovascular conditions in patients with chronic hypoparathyroidism: a retrospective cohort study","volume":"38","author":"Gosmanova","year":"2021","journal-title":"Adv Ther"},{"issue":"4","key":"2025100710005545200_lvaf169-B6","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1007\/s12325-021-01658-1","article-title":"Risk of chronic kidney disease and estimated glomerular filtration rate decline in patients with chronic hypoparathyroidism: a retrospective cohort study","volume":"38","author":"Gosmanova","year":"2021","journal-title":"Adv Ther"},{"issue":"2","key":"2025100710005545200_lvaf169-B7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11154-020-09613-1","article-title":"Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review: renal disease in chronic hypoparathyroidism","volume":"22","author":"Gosmanova","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"issue":"12","key":"2025100710005545200_lvaf169-B8","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1002\/jbmr.4673","article-title":"Complications, symptoms, presurgical predictors in patients with chronic hypoparathyroidism: a systematic review","volume":"37","author":"Yao","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2025100710005545200_lvaf169-B9","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-18-0609","article-title":"Standards of care for hypoparathyroidism in adults: a Canadian and international consensus","volume":"180","author":"Khan","year":"2019","journal-title":"Eur J Endocrinol."},{"issue":"8","key":"2025100710005545200_lvaf169-B10","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1210\/jc.2016-1477","article-title":"Epidemiology and health-related quality of life in hypoparathyroidism in Norway","volume":"101","author":"Astor","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025100710005545200_lvaf169-B11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11657-020-00759-8","article-title":"The effects of patient and disease-related factors on the quality of life in patients with hypoparathyroidism","volume":"15","author":"Hepsen","year":"2020","journal-title":"Arch Osteoporos"},{"issue":"1","key":"2025100710005545200_lvaf169-B12","doi-asserted-by":"publisher","first-page":"e210379","DOI":"10.1530\/EC-21-0379","article-title":"Low health-related quality of life in hypoparathyroidism and need for PTH analog","volume":"11","author":"Kontogeorgos","year":"2022","journal-title":"Endocr Connect"},{"issue":"2","key":"2025100710005545200_lvaf169-B13","doi-asserted-by":"publisher","first-page":"e10586","DOI":"10.1002\/jbm4.10586","article-title":"The influence of conventional treatment on symptoms and complaints in patients with chronic postsurgical hypoparathyroidism","volume":"6","author":"Stamm","year":"2022","journal-title":"JBMR Plus"},{"issue":"7","key":"2025100710005545200_lvaf169-B14","doi-asserted-by":"publisher","first-page":"e10368","DOI":"10.1002\/jbm4.10368","article-title":"Quantification of symptom load by a disease-specific questionnaire HPQ 28 and analysis of associated biochemical parameters in patients with postsurgical hypoparathyroidism","volume":"4","author":"Wilde","year":"2020","journal-title":"JBMR Plus"},{"issue":"1","key":"2025100710005545200_lvaf169-B15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/jbmr.4726","article-title":"Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial","volume":"38","author":"Khan","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025100710005545200_lvaf169-B16","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1210\/jc.2018-02430","article-title":"Quality of life in hypoparathyroidism improves with rhPTH (1-84) throughout 8 years of therapy","volume":"104","author":"Tabacco","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025100710005545200_lvaf169-B17","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1210\/jc.2017-01471","article-title":"Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism","volume":"103","author":"Vokes","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2025100710005545200_lvaf169-B18","author":"US Food and Drug Administration"},{"key":"2025100710005545200_lvaf169-B19","author":"Takeda Pharmaceuticals International AG"},{"issue":"12","key":"2025100710005545200_lvaf169-B20","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1002\/jbmr.4671","article-title":"The second international workshop on the evaluation and management of hypoparathyroidism","volume":"37","author":"Khan","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025100710005545200_lvaf169-B21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12902-021-00888-2","article-title":"The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics","volume":"21","author":"Gittoes","year":"2021","journal-title":"BMC Endocrin Disord"},{"key":"2025100710005545200_lvaf169-B22","volume-title":"User\u2019s Manual for the SF-36v2 Health Survey","author":"Ware","year":"2007"},{"issue":"6","key":"2025100710005545200_lvaf169-B23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"5","key":"2025100710005545200_lvaf169-B24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"2025100710005545200_lvaf169-B25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/PROM.S179310","article-title":"Psychometric evaluation of the hypoparathyroidism symptom diary","volume":"10","author":"Coles","year":"2019","journal-title":"Patient Relat Outcome Meas"},{"issue":"8","key":"2025100710005545200_lvaf169-B26","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s12325-019-00999-2","article-title":"Development of a patient-reported outcome measure for chronic hypoparathyroidism","volume":"36","author":"Martin","year":"2019","journal-title":"Adv Ther"},{"key":"2025100710005545200_lvaf169-B27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2147\/PROM.S414794","article-title":"Psychometric analysis of the patient-reported hypoparathyroidism symptom diary symptom subscale using data from two clinical trials","volume":"14","author":"Nelson","year":"2023","journal-title":"Patient Relat Outcome Meas"},{"issue":"2","key":"2025100710005545200_lvaf169-B28","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-15-0628","article-title":"European society of endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults","volume":"173","author":"Bollerslev","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2025100710005545200_lvaf169-B29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.pop.2008.01.007","article-title":"Disorders involving calcium, phosphorus, and magnesium","volume":"35","author":"Moe","year":"2008","journal-title":"Prim Care"},{"issue":"3","key":"2025100710005545200_lvaf169-B30","first-page":"265","article-title":"Canadian normative data for the SF-36 health survey. Canadian multicentre osteoporosis study research group","volume":"163","author":"Hopman","year":"2000","journal-title":"CMAJ"},{"issue":"1","key":"2025100710005545200_lvaf169-B31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12955-017-0625-9","article-title":"Measurement properties and normative data for the Norwegian SF-36: results from a general population survey","volume":"15","author":"Garratt","year":"2017","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"2025100710005545200_lvaf169-B32","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1001\/archinte.164.9.1010","article-title":"Depression and C-reactive protein in US adults: data from the third national health and nutrition examination survey","volume":"164","author":"Ford","year":"2004","journal-title":"Arch Intern Med"},{"issue":"1","key":"2025100710005545200_lvaf169-B33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s10194-020-01108-3","article-title":"Pain rates in general population for the period 1991-2015 and 10-years prediction: results from a multi-continent age-period-cohort analysis","volume":"21","author":"Guido","year":"2020","journal-title":"J Headache Pain"},{"issue":"8","key":"2025100710005545200_lvaf169-B34","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.jpsychires.2011.03.006","article-title":"Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness","volume":"45","author":"McLean","year":"2011","journal-title":"J Psychiatr Res"},{"issue":"1","key":"2025100710005545200_lvaf169-B35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0002-9343(82)90567-8","article-title":"Effects of low-calcium diet on urine calcium excretion, parathyroid function and serum 1, 25(OH)2D3 levels in patients with idiopathic hypercalciuria and in normal subjects","volume":"72","author":"Coe","year":"1982","journal-title":"Am J Med"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/4\/428\/64536470\/lvaf169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/4\/428\/64536470\/lvaf169.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:19:25Z","timestamp":1759846765000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/193\/4\/428\/8276748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf169","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,30]]}}}